OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers & Dementia is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	2446
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	1796
Locus coeruleus hyperactivity in middle age may be associated with better cognitive performance	1354
Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID‐19: A Prospective Longitudinal Study	1309
Alzheimer's disease‐induced phagocytic microglia express a specific profile of coding and non‐coding RNAs	625
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab	431
Diversity, Equity and Inclusivity‐ Low and Middle Income countries and the Lancet commission	355
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease	345
Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study	282
Prevalence of neuropsychiatric conditions and cognitive impairment in two parallel, aging study cohorts from rural and urban India	210
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	201
The Design of SPRINT MIND and SPRINT MIND 2020	181
The Global Neurodegeneration Proteomics Consortium ‐ Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging	181
Rapid discovery and optimization of novel brain shuttles and shuttle‐enabled anti‐amyloid therapeutics using multiplexed in vivo biologics design	172
Survey on knowledge of Uruguayan neurologist about the FINGER intervention	166
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory	164
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease	151
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances	148
The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis	143
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study	137
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease	131
Social Engagement as a Protective Factor for Cognition in Older Adults: Examining Sex and Race Differences	123
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	118
The Types and Consistency of Participant‐Specified Proxies During SPRINT	118
Neural flexibility as a promising biomarker for Alzheimer’s Disease	118

Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers: an overview of the HEAD study cohort	112
Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)	112
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease	103
Subjective cognitive decline across ethnoracial groups in the A4 study	101
Identifying individuals with non‐AD co‐pathologies: A precision medicine approach to clinical trials in sporadic AD	97
Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID‐19 hospitalization	91
Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial	89
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium	88
Evaluation of Two Plasma pTau217 Simoa Assays Against Amyloid‐PET	87
Lean mass, grip strength, and hospital‐associated disability among older adults in Health ABC	86
An international core outcome set for primary progressive aphasia (COS‐PPA): Consensus‐based recommendations for communication interventions across research and clinical settings	83
“Brain‐IT”: Exergame training with biofeedback breathing in neurocognitive disorders	83
Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort	83
Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis	83
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	81
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method	81
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China	80
The effect of prolonged lockdown due to COVID‐19 on demented patients of different stages and on their caregivers	78
The dementia policies in Australia relating to the COVID‐19 pandemic	75
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline	74
The association between diabetes and Alzheimer’s disease pathophysiology	74
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	74
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	74
Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults	72
Fish intake and MRI burden of cerebrovascular disease in older adults	72
The impact of the COVID‐19 pandemic on cognitive health	72
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	72
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	71
The troubles and needs of family caregivers of older adults with moderate to severe dementia	71
Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning	71
Association of neighborhood socioeconomic disadvantage and cognitive decline	71
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	71
Issue Information	71
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	70
Development of pyroptosis inhibitors for Alzheimer’s disease	69
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	67
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	66
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	66
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	65
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	65